AG
RARE icon

Artal Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

Artal Group’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-50,000
Closed -$3.55M – 100
2016
Q3 		$3.55M Buy
+50,000
New +$3.19M 0.07% 67

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Artal Group's RARE Position: Q3 2024 in Review

Artal Group sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2024, closing a stake of 275,000 shares — an estimated $11.3M sold.

Artal Group first reported a position in RARE in Q2 2016 and held it in 8 quarters. The position peaked at $11.3M in Q2 2024. 300 funds tracked by Wall St. Rank hold RARE as of Q3 2024.

  • Artal Group reported no remaining Ultragenyx Pharmaceutical position as of Q3 2024 after selling out during the quarter.
  • Artal Group sold 275,000 Ultragenyx Pharmaceutical shares in Q3 2024, an estimated $11.3M.
  • Artal Group first reported a position in Ultragenyx Pharmaceutical in Q2 2016 and held it in 8 quarters.
  • Artal Group's Ultragenyx Pharmaceutical position peaked at $11.3M in Q2 2024.
  • 300 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.